An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs DAS 181 (Primary)
- Indications Parainfluenza virus infections
- Focus Adverse reactions
- Sponsors Ansun Biopharma
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 08 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Jan 2014 New source identified and integrated. (M.D. Anderson Cancer Center; 2013-0579 )